Prostaglandin-Associated Periorbitopathy Symptom Alleviation After Switching Prostaglandin F Receptor Agonist to EP2 Receptor Agonist in Patients with Glaucoma
Journal of Ocular Pharmacology and Therapeutics · 01.02.2023 · 39 (1) · 63-69
DOI: 10.1089/jop.2022.0096 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Ocular Pharmacology and Therapeutics, online erschienen am 25.01.2023. Verfasst von Rei Sakata und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Graduate of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Eyelid Diseases, Orbital Diseases, Glaucoma, Prostaglandins F, Synthetic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Purpose
Prostaglandin-associated periorbitopathy in patients with glaucoma is reportedly not caused by EP2 agonist, but it has been a cosmetic problem with prostaglandin F receptor (FP) agonists. In this study, patients with prostaglandin-associated periorbitopathy on FP agonists were switched to EP2 agonist and changes were investigated.
Methods
Patients complaining of prostaglandin-associated periorbitopathy were included. The FP agonist was switched to EP2 agonist (omidenepag isopropyl), and patients were followed up for 7 months. Frontal photographs were taken at every visit, and objective changes in deepening of the upper eyelid sulcus were assessed by three observers. Subjective questionnaires (self-awareness of deepening of the upper eyelid sulcus, eyelid/peri-eyelid skin pigmentation, eyelash elongation, and conjunctival hyperemia) were acquired at the start and the endpoint. Factors associated with the change of prostaglandin-associated periorbitopathy were investigated using logistic regression analysis.
Results
Included were 23 eyes of 23 patients (17 women; 60.6 years). At 7 months, objective deepening of the upper eyelid sulcus improved by 76%. The subjective questionnaires showed that deepening of the upper eyelid sulcus improved in 95%, eyelid/peri-eyelid skin pigmentation in 76%. The less extent of myopia was a significant factor in the eyes with improved eyelid/peri-eyelid skin pigmentation. After switching, no change in intraocular pressure or visual acuity was observed ( P ≥ 0.22).
Conclusion
Switching to omidenepag isopropyl increased patient satisfaction and might be the first step to lightening deepening of the upper eyelid sulcus and eyelid/peri-eyelid skin pigmentation. It was suggested that pigmentation may be more easily improved in nonmyopic eyes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Graduate of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
- Yotsuya Shirato Eye Clinic, Tokyo, Japan.
- Santen Pharmaceutical Co., Ltd., Osaka, Japan.
ORCID-Profile: Rei Sakata
Zitieren
APA
Sakata, R., Fujishiro, T., Saito, H., Nakamura, N., Honjo, M., Shirato, S., Miyamoto, E., Yamada, Y., & Aihara, M. (2023). Prostaglandin-Associated Periorbitopathy Symptom Alleviation After Switching Prostaglandin F Receptor Agonist to EP2 Receptor Agonist in Patients with Glaucoma. Journal of Ocular Pharmacology and Therapeutics, 39(1), 63-69. https://doi.org/10.1089/jop.2022.0096
Vancouver
Sakata R, Fujishiro T, Saito H, Nakamura N, Honjo M, Shirato S, et al. Prostaglandin-Associated Periorbitopathy Symptom Alleviation After Switching Prostaglandin F Receptor Agonist to EP2 Receptor Agonist in Patients with Glaucoma. Journal of Ocular Pharmacology and Therapeutics. 2023;39(1):63-69. doi:10.1089/jop.2022.0096
BibTeX
@article{Sakata2023,
author = {Sakata, Rei and Fujishiro, Takashi and Saito, Hitomi and Nakamura, Natsuko and Honjo, Megumi and Shirato, Shiroaki and Miyamoto, Etsuyo and Yamada, Yoshiaki and Aihara, Makoto},
title = {Prostaglandin-Associated Periorbitopathy Symptom Alleviation After Switching Prostaglandin F Receptor Agonist to EP2 Receptor Agonist in Patients with Glaucoma},
journal = {Journal of Ocular Pharmacology and Therapeutics},
year = {2023},
volume = {39},
number = {1},
pages = {63--69},
doi = {10.1089/jop.2022.0096}
}
EUVIMED